Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | SCN4A | P35499 | 1/20 | 0.42 |
| ▸ | MPL | P40238 | 4/20 | 0.39 |
| ▸ | PTGES | O14684 | 11/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | MYC | P01106 | 1/20 | 0.36 |
| ▸ | WDR5 | P61964 | 1/20 | 0.36 |
| ▸ | RORB | Q92753 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30953779 | 0.85 | EPHX2 (0.38) | EPHX2SCN4AMPLPTGESPTGS1 | |
| SCHEMBL30953678 | 0.84 | EPHX2 (0.39) | EPHX2SCN4AMPLPTGESMYC | |
| SCHEMBL30953589 | 0.84 | EPHX2 (0.40) | EPHX2SCN4AMPLPTGESPTGS1 | |
| SCHEMBL30953884 | 0.83 | EPHX2 (0.41) | EPHX2SCN4AMPLPTGESPTGS1 | |
| SCHEMBL30953616 | 0.83 | EPHX2 (0.40) | EPHX2SCN4AMPLMYCWDR5 | |
| SCHEMBL30953648 | 0.82 | EPHX2 (0.42) | EPHX2SCN4AMPLMYCWDR5 | |
| SCHEMBL30953748 | 0.82 | EPHX2 (0.42) | EPHX2SCN4AMPLMYCWDR5 | |
| SCHEMBL30953683 | 0.82 | EPHX2 (0.42) | EPHX2SCN4AMPLMYCWDR5 | |
| SCHEMBL30953764 | 0.81 | EPHX2 (0.41) | EPHX2SCN4AMPLMYCWDR5 | |
| SCHEMBL30953693 | 0.81 | EPHX2 (0.41) | EPHX2SCN4AMPLMYCWDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024140431-A1 | COMPOUNDS COMPRISING HETEROARYL RINGS AND COMPOSITIONS AND METHODS THEREOF | IONGEN THERAPEUTICS CO., LTD. (CN) | 2024-07-04 | — | — | WO | disclosed |